JSP chooses Amneal after ceasing Lannett
Amneal Pharmaceuticals is to stake a claim in “one of the most compelling generic product markets in the United States today” by signing a 10-year licence and supply agreement with Jerome Stevens Pharmaceuticals (JSP) for levothyroxine sodium tablets, after the family-owned company opted against renewing its existing agreement with Lannett (see page 14).
You may also be interested in...
In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.
Teva has added another major dermatology brand to its armory, with the launch of an authorized generic version of Galderma’s Epiduo Forte Gel.
Amgen management paid close attention to the company’s biosimilar portfolio and pipeline during several recent calls with investors, including what differentiates the firm from its rivals in the biosimilars space.